OptiNose’s (OPTN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of OptiNose (NASDAQ:OPTN) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Separately, Lake Street Capital lifted their price objective on OptiNose from $3.00 to $4.00 and gave the company a buy rating in a research report on Monday, March 18th.

OptiNose Stock Performance

Shares of OptiNose stock opened at $0.86 on Monday. OptiNose has a 1-year low of $0.80 and a 1-year high of $2.10. The company’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.32.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $19.87 million during the quarter, compared to the consensus estimate of $19.90 million. During the same period in the prior year, the business posted ($0.17) earnings per share. As a group, research analysts predict that OptiNose will post -0.26 EPS for the current year.

Insider Transactions at OptiNose

In related news, insider Michael F. Marino III sold 15,059 shares of OptiNose stock in a transaction on Monday, March 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,310.92. Following the transaction, the insider now owns 602,268 shares in the company, valued at approximately $1,132,263.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Michael F. Marino III sold 15,059 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $1.88, for a total value of $28,310.92. Following the transaction, the insider now directly owns 602,268 shares of the company’s stock, valued at approximately $1,132,263.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ramy A. Mahmoud sold 19,198 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $1.88, for a total transaction of $36,092.24. Following the sale, the chief executive officer now directly owns 1,331,278 shares of the company’s stock, valued at $2,502,802.64. The disclosure for this sale can be found here. Insiders sold a total of 89,477 shares of company stock valued at $138,078 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On OptiNose

Several institutional investors have recently bought and sold shares of the stock. HighMark Wealth Management LLC purchased a new stake in OptiNose in the 1st quarter worth $36,000. Palumbo Wealth Management LLC bought a new stake in shares of OptiNose in the fourth quarter worth about $33,000. Assenagon Asset Management S.A. bought a new stake in shares of OptiNose in the fourth quarter worth about $47,000. FMR LLC lifted its position in shares of OptiNose by 0.3% in the third quarter. FMR LLC now owns 14,848,870 shares of the company’s stock worth $18,264,000 after buying an additional 47,564 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. boosted its stake in OptiNose by 1.4% during the third quarter. Kingdon Capital Management L.L.C. now owns 3,699,237 shares of the company’s stock valued at $4,550,000 after buying an additional 50,000 shares during the last quarter. 85.60% of the stock is owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.